HOME >> BIOLOGY >> NEWS
Progesterone therapy and preterm birth: More evidence helps identify women who can benefit

WHITE PLAINS, N.Y., AUG. 2, 2005 Two major studies published today in The New England Journal of Medicine can help doctors better identify pregnant women at risk for preterm delivery who can benefit from progesterone treatment, the March of Dimes Foundation said today.

In one large multi-center trial led by Eduardo B. Fonseca, M.D., women with short cervix (most of whom had no prior history of preterm birth) who received progesterone suppository treatment between 24 and 34 weeks gestation had a greatly reduced rate of preterm birth.

Another large multi-center trial led by Dwight J. Rouse, M.D., found that weekly injections of 17P (17 alpha-hydroxyprogesterone caproate, a derivative of progesterone) between 16 and 35 weeks gestation did not reduce the rate of preterm birth among women carrying twins.

Premature birth is a growing problem in the United States and a leading killer of newborns, said Michael Katz, senior vice president for Research and Global Programs of the March of Dimes. With this new information, physicians will have a better idea of how to identify those women who are most likely to benefit from progesterone treatment from those who are not.

Dr. Katz noted that pathways to preterm birth may differ substantially between singleton and twin gestations. For example, progesterone may be more effective against some pathway that does not involve the uterine over-distention seen in twin pregnancy.

We need more research into the underlying causes of prematurity to help women with other risk factors, Dr. Katz said.


'"/>

Contact: Elizabeth Lynch
elynch@marchofdimes.com
914-997-4286
March of Dimes Foundation
1-Aug-2007


Page: 1

Related biology news :

1. Progesterone injections do not prevent preterm birth in twin pregnancies
2. Testosterone replacement therapy: How safe for aging men?
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... BOSTON (PRWEB) , ... August 19, 2020 , ... ... , the premier conference and expo uniting life science, data science, informatics and ... keynote sessions. , “In this period of uncertainty and change, Bio-IT takes the ...
(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a fast-growing provider ... Eric Chen and Jessica Wong have joined the company’s leadership team as Vice ... Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an innovative cloud-based ...
(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical ... this project is to develop, optimize, and scale-up a highly efficient mammalian cell ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... COLLEGE STATION, Texas (PRWEB) , ... July 29, ... ... pre-qualified cleanroom solutions today announced the launch of its new tagline, “BUILDING FOR ... within the biopharmaceutical industry and around the globe, requiring fast track capacity to ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® Respiratory ... 16 countries, has reached its 20th anniversary of worldwide use. Introduced in the ... top universities including University of Pennsylvania, University of Michigan, University of Maryland, University ...
(Date:7/18/2020)... ... 16, 2020 , ... Medial EarlySign , a leader ... of high-burden diseases, and Centric Consulting, a business and technology consulting firm, today ... data in order to identify and prioritize patients for care. , Combining Centric’s ...
(Date:7/10/2020)... ... 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will ... SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the ...
Breaking Biology Technology:
Cached News: